20 Nov 2012, BioSpectrum Bureau , BioSpectrum
Singapore: Trifecta Clinical joined the board of directors for the Asia Training Consortium (ATC), which is a group of pharmaceutical companies, clinical research organizations and regional associations that have pooled resources to deliver quality training for the development of clinical research professionals in the Asia Pacific region.
"We're thrilled to be a part of an organization that is meeting an acute need in clinical development in Asia," says Trifecta Clinical CEO, Mr Dave Young. "Our technology and training experience complements the strong industry partners who make up the ATC."
"Trifecta has a track record of effectively delivering clinical training around the world," says ATC board chairman Mr John Constantine, who also serves as the executive director and dean of the Merck Polytechnic Institute. "They have the ability to provide a very quick start-up program on a platform that the ATC can continue to grow with as we help meet Asia's rapidly increasing needs. As a technology company, Trifecta rounds out our Board's membership."
Trifecta has developed an application platform for training and managing clinical research sites. Trifecta will leverage this expertise for the ATC by providing training to future members of the clinical research community. Trifecta is also sponsoring a working group to create an open Extensible Markup Language (XML) standard for exchanging clinical training information - Clinical Training Interoperability Open Standard (CTIOS). The creation of this open standard will allow authorized organizations to easily communicate training status in compliance with privacy regulations and security best practices.
Trifecta joins Covance and Novartis as the three non-permanent member organizations serving a three-year term. The six permanent member organizations are Merck, Pfizer, Bayer, RPS, Orchestrall and the Pan-Asian Clinical Research Association (PACRA).